4TO Stock Overview
Develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Mainz Biomed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$1.53 |
| 52 Week Low | US$0.17 |
| Beta | 0.076 |
| 11 Month Change | -28.72% |
| 3 Month Change | -36.58% |
| 1 Year Change | -81.85% |
| 33 Year Change | -97.70% |
| 5 Year Change | n/a |
| Change since IPO | -97.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4TO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -16.9% | -0.7% | -0.02% |
| 1Y | -81.8% | -17.2% | 8.2% |
Return vs Industry: 4TO underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 4TO underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 4TO volatility | |
|---|---|
| 4TO Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4TO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4TO's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 68 | Guido Baechler | mainzbiomed.com |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Mainz Biomed N.V. Fundamentals Summary
| 4TO fundamental statistics | |
|---|---|
| Market cap | €5.22m |
| Earnings (TTM) | -€21.61m |
| Revenue (TTM) | €880.79k |
5.8x
P/S Ratio-0.2x
P/E RatioIs 4TO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4TO income statement (TTM) | |
|---|---|
| Revenue | US$917.20k |
| Cost of Revenue | US$376.25k |
| Gross Profit | US$540.96k |
| Other Expenses | US$23.05m |
| Earnings | -US$22.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 58.98% |
| Net Profit Margin | -2,453.86% |
| Debt/Equity Ratio | -166.8% |
How did 4TO perform over the long term?
See historical performance and comparison